Document Type
Article
Rights
Available under a Creative Commons Attribution Non-Commercial Share Alike 4.0 International Licence
Disciplines
3. MEDICAL AND HEALTH SCIENCES
Abstract
The applications of Raman micro-spectroscopy have been extended in recent years into the field of clinical medicine, and specifically in cancer research, as anon-invasive diagnostic method in vivo and ex vivo, and the field of pharmaceutical development as a label free predictive technique for new drug mechanisms of action in vitro. To further illustrate its potential for such applications, it is important to establish its capability to fingerprint drug mechanisms of action and different cellular reactions. In this study, cytotoxicity assays were employed to establish the toxicity profiles for 48 and 72 hrs exposure of lung cancer cell lines, A549 and Calu-1, after exposure to Actinomycin D (ACT) and Raman micro-spectroscopy was used to track its mechanism of action at subcellular level and subsequent cellular responses. Multivariate data analysis was used to elucidate the spectroscopic signatures associated with ACT chemical binding and cellular resistances. Results show that the ACT uptake and mechanism of action are similar in the two cell lines, while A549 cells exhibits spectral signatures of resistance to apoptosis related to its higher chemoresistance to the anticancer drug ACT. The observations are discussed in comparison to previous studies of the similar anthracyclic chemotherapeutic agent Doxorubicin.
DOI
https://doi.org/10.1002/jbio.201700112
Recommended Citation
Farhane, Z., Bonnier, F. and Byrne, H.J. (2017). An in vitro study of the interaction of the chemotherapeutic drug Actinomycin D with lung cancer cell lines using Raman micro-spectroscopy. Journal of Biophotonics, Jul 13, Epub ahead of print. doi:10.1002/jbio.201700112
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.
Publication Details
Journal of Biophotonics. 2017 Jul 13. [Epub ahead of print]